ライフサイエンスコーパス: virus-like particle

1 e short glycan displayed at the surface of a virus-like particle.

2 r HRV 2/4/6 virus-like particles but not 2/6 virus-like particles.

3 embrane are similar to the known contacts in virus-like particles.

4 on of this dimer is essential for budding of virus-like particles.

5 filament formation and a lack of budding of virus-like particles.

6 that GP may enhance BST2 incorporation into virus-like particles.

7 e of plasma membrane PS in assembly of Ebola virus-like particles.

8 ic strength DeltaGag assembles into immature virus-like particles.

9 tein Gag co-opts this process for budding of virus-like particles.

10 s prior to and during in vitro assembly into virus-like particles.

11 accurate determination of the composition of virus-like particles.

12 gle DNA molecules to finally form rod-shaped virus-like particles.

13 a heterotoma (Figitidae) produces venom with virus-like particles.

14 mplexes assembled in vitro and to the RNA in virus-like particles.

15 y1 antisense transcripts that associate with virus-like particles.

16 ts are now recognised to harbour viruses and virus-like particles.

17 alysis performed using virus pseudotypes and virus-like particles.

18 tion and affected protein incorporation into virus-like particles.

19 l in minigenome assays and incorporated into virus-like particles.

20 a virus Ankara (MVA) expressing HIV-1 Env on virus-like particles.

21 orbornene (PNB) when attached to icosahedral virus-like particles.

22 even while it antagonizes the entrapment of virus-like particles.

23 MVA expressing noninfectious SIV macaque 239 virus-like particles.

24 ncy as well as different morphology lines of virus-like particles.

25 Here, influenza virus-like particles(4) carrying wild-type haemagglutini

26 lizing antibodies, N90-VRC38.01-11, by using virus-like particles and conformationally stabilized Env

27 ication of the capture-stabilize approach to virus-like particles and demonstrated its utility analyz

28 Similarly, Vpx-containing virus-like particles and deoxynucleosides added to the c

29 ts, we examine HIV-1 Gag-mediated budding of virus-like particles and find that depleting Vps4 traps

30 Ty1 Gag comprises the capsid of virus-like particles and provides nucleic acid chaperone

31 domain greatly affect the production of both virus-like particles and replicon particles.

32 Z has been shown to mediate the formation of virus-like particles and to inhibit viral RNA synthesis,

33 le-chain antibody HJT-R3-A9 to identify both virus-like particles and virus-containing fecal samples.

34 ntisera from horses hyperimmunized with EBOV virus-like particles, and tested the post-exposure effic

35 , we determined structures of Qbeta virions, virus-like particles, and the Qbeta-MurA complex using s

36 sfected cell cultures, minireplicon systems, virus-like particles, and virus infections, we determine

37 Additionally, budding and release of virus-like particles are prevented in M mutants that fai

38 Here we show that virus-like particles are relatively less abundant at hig

39 Due to the absence of viral genes, the virus-like particles are unable to spread or cause disea

40 o have implications for the potential use of virus-like particles as protein delivery tools.

41 ynthetic or natural polymers, liposomes, and virus-like particles as well as nonbiodegradable NPs lik

42 we report the crystal structure of an Orsay virus-like particle assembled from recombinant capsid pr

43 gene of the yeast Ty1 element that disrupts virus-like particle assembly in a dose-dependent manner.

44 Virus-like particle assembly was nonetheless rescued eff

45 nt protein was efficiently incorporated into virus-like particles at elevated temperature, the progen

46 antibodies were measured at baseline using a virus-like particle-based ELISA assay.

47 PV-18 immunoglobulin G (IgG) levels by an L1 virus-like particle-based enzyme-linked immunosorbent as

48 or HPV antibodies (4 types) by a multiplexed virus-like particle-based immunoglobulin G direct enzyme

49 With the goal of developing a virus-like particle-based vaccine based on dense bodies

50 NA followed by boosting with Kunjin replicon virus-like particles both encoding a modified Ebola glyc

51 but not LGG to Wa HRV particles or HRV 2/4/6 virus-like particles but not 2/6 virus-like particles.

52 mising clathrin-dependent internalization of virus-like particles by DC-SIGN.

53 e report here the preparation of filamentous virus-like particles by the encapsulation of a linear or

54 Virus-like particles can be formed by self-assembly of c

55 ric and trimeric complexes are on pathway to virus-like particle (capsid) formation.

56 rmined the cryo-EM structures of chikungunya virus-like particles complexed with antibody fragments (

57 Env-specific B cells after immunization with virus-like particles containing GagPol and Env.

58 oneedle (MN) patch for skin vaccination with virus-like particles containing influenza virus heterolo

59 assembly is partially restored, although the virus-like particles created are incomplete, implying th

60 rated with influenza HA-antigens in chimeric virus-like particles (cVLPs), in boosting strong protect

61 s with retroviral nonreplicating vectors and virus-like particles demonstrated that the immunosuppres

62 d-based nanoparticles, liposomes, virosomes, virus-like particles, dendrimers and the like, plus macr

63 s-like phage, poorly represented in existing virus like particle-derived viral metagenomes.

64 ied vaccinia Ankara (MVA) vaccines producing virus-like particles displaying trimeric membrane-bound

65 Similarly, upon vaccination with virus-like particles displaying vesicular stomatitis vir

66 large amounts of penton-dodecahedra (PtDd), virus-like particles, during replication.

67 , this masking does not explain the observed virus-like particle egress enhancement.

68 efficient approach for production of stable virus-like particles encapsidating nonnative RNAs or oth

69 e Gag is sufficient to drive the assembly of virus-like particles even in the absence of gRNA binding

70 infecting mosquitoes and a vaccine based on virus-like particles expressing envelope proteins.

71 Furthermore, virus-like particles expressing only the receptor-bindin

72 t reduction of SAMHD1 levels with the use of virus-like particles expressing Vpx- and SAMHD1-specific

73 DDMM and MMM vaccinations with virus-like particle-expressing immunogens elicited durab

74 rotein nanoparticles, such as viral capsids, virus-like particles, ferritin, heat-shock proteins and

75 during inflammation, and conjugated them to virus-like particles, followed by immunization of mice.

76 ng that the kinetics of self-assembly of our virus-like particles follows a previous model developed

77 tein nanocontainers for drug delivery and of virus-like particles for vaccination.

78 NP adjuvants mixed with soluble SIV Env or a virus-like particle form of Env (VLP) induces potent and

79 sential for plasma membrane localization and virus-like particle formation and release from cells.

80 Analysis of virus-like particles from a filtrate found to reduce sym

81 The B3-containing virus-like particle has been crystallised and its struct

82 human papillomavirus type 16, 18, 6, and 11 virus-like particles have been introduced in many develo

83 als of vaccines consisting of nonreplicating virus-like particles have shown promise.

84 rm cage-like structures, such as viruses and virus-like particles, have been of particular interest s

85 Importantly, high-Env virus-like particles (hVLPs) were produced with a manife

86 Structures of chikungunya virus-like particles in complex with strongly neutralizi

87 ntibodies elicited by immunization via Pfs25 virus-like particles in human immunoglobulin loci transg

88 combinant FMDV subunit antigens and produced virus-like particles in mammalian and bacterial cells.

89 (1,2)fucosylated motifs and binding of GII.4 virus-like particles in nonsecretors' mucosa were associ

90 es of GII.4-2006, GII.4-2009, and GII.4-2012 virus-like particles in surrogate neutralization/blockad

91 From its ability to assemble into virus-like particles in vitro, we infer that RSV Gag is

92 ons of enteroviruses and enterovirus-related virus-like particles, including their entry mechanisms i

93 er, how VP40 interacts with the PM and forms virus-like particles is for the most part unknown.

94 shotgun pyrosequencing of DNA purified from virus-like particles isolated from a stool sample collec

95 Furthermore, although it was found in IAP virus-like particles, it did not affect their incorporat

96 e to code for all viral proteins and produce virus-like particles, it is not known if these virus par

97 V vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprote

98 titution, were efficiently incorporated into virus-like particles lacking infectivity.

99 Moloney murine leukemia virus-like particles (M-VLPs) were complexed with chitos

100 Non-infectious murine leukemia virus-like particles (M-VLPs) were electrostatically com

101 s have been used to study Gag expression and virus-like particle morphology among representative retr

102 t these limitations, we used enzymatic Nipah virus-like-particles (NiVLPs) and developed new flow vir

103 eptides for those that bind to Norwalk virus virus-like particles (NV VLPs).

104 e extended conformation, Gag forms spherical virus-like particles of approximately 100-nm diameter.

105 the authors use plants to express stabilized virus-like particles of type 3 poliovirus that can induc

106 Finally, virus-like particles of unknown identity were observed i

107 rmed on assemblies (P dimer, P particle, and virus-like particle) of recombinant viral capsid protein

108 ants and carriers, as well as those based on virus-like particles offer several key advantages to hel

109 different norovirus genotypes as recombinant virus-like particles or in clinical samples was dependen

110 r proteasomal degradation using specialized, virus-like particles-potentiates the cytotoxicity of Ara

111 haracteristics of epitopes found on the full virus-like particle precisely, suggesting that these nan

112 We show that our virus-like particles protect DNA against enzymatic degra

113 ing streams, monitor assembly of viruses and virus-like particles, rapidly identify viruses from biol

114 aling events involved in the uptake of these virus-like particles remain ill-defined.

115 mRNA LNPs encoding prM-E genes that produced virus-like particles resulted in high neutralizing antib

116 tinct Fabs reactive with Norwalk recombinant virus-like particles (rVLPs) were recovered, with estima

117 nt correlation between the level of in vitro virus-like particle secretion, the elicited antibody res

118 Remarkably, uniform virus-like particles self-assemble in a process that app

119 Hepatitis E Virus-like particles self-assemble in to noninfectious n

120 d compared the results with prM/E containing virus-like particle-specific MAC-ELISA (VLP-MAC-ELISA).

121 were recognized by murine antisera to HPV58 virus-like particles, suggesting that these are antibody

122 veloping a synthetically produced stabilized virus-like particle (sVLP)-based vaccine with D antigeni

123 ce TLR2 ligation was defined using synthetic virus-like particles (SVLPs) carrying hydrophobic TLR2 P

124 tablishment of a transcriptionally competent virus-like particle (tc-VLP) system for CCHFV.

125 96)-Pol-Nef(CN54) polyprotein as Gag-derived virus-like particles (termed NYVAC-C-KC).

126 ural empty particle, and a recombinant CVA16 virus-like particle that does not contain the viral geno

127 P40 in mammalian cells is sufficient to form virus-like particles that are nearly indistinguishable f

128 paramyxoviruses) M (matrix) protein-derived virus-like particles that bud from GSL-enriched plasma m

129 , viruses are often accompanied by defective virus-like particles that carry large deletions in their

130 ly, by comparing the Qbeta virion with Qbeta virus-like particles that lack a maturation protein, we

131 rectly processed HERV-K (HML-2) proteins and virus-like particles that were recognized by anti-HERV-K

132 Using canine norovirus virus-like particles, this work shows that representativ

133 nd the biosensing efficacy of Tobacco mosaic virus-like particle (TMV VLP) sensing probes using an im

134 uctions for the wild-type virus and an empty virus-like particle, to 3.4 A and 3.0 A resolution, resp

135 A cholesterol-dependent virus-like particle trap assay, based on co-expression o

136 and transcription- and replication-competent virus-like particle (trVLP) systems, allow modeling of t

137 We tested a virus-like particle vaccine against Ebola virus, a leadi

138 g disease after intranasal immunization with virus-like particle vaccine containing the RSV fusion pr

139 m clinical trials of an human papillomavirus virus-like particle vaccine suggest that it may be possi

140 We have devised a virus like particle (VLP) carrier based on the hepatitis

141 and its expression is required for EBOV VP40 virus-like particle (VLP) budding.

142 ain protection provided by a multivalent NoV virus-like particle (VLP) candidate vaccine in human vol

143 e-escalation, open-label clinical trial of a virus-like particle (VLP) chikungunya virus vaccine, VRC

144 In this study, we report a virus-like particle (VLP) for building a 3D plasmonic na

145 ns were developed and tested in mice using a virus-like particle (VLP) format for the elicitation of

146 of bivalent synbody affinity ligands using a virus-like particle (VLP) from the 2006 GII.4 Minerva st

147 ited following vaccination or preclinical L1 virus-like particle (VLP) immunization or by monoclonal

148 hly protective CSP-based P. vivax vaccine, a virus-like particle (VLP) known as Rv21, able to provide

149 is study, we constructed a bivalent chimeric virus-like particle (VLP) presenting the VP1 (aa208-222)

150 Virus-like particle (VLP) production assays were used to

151 We have reported that a virus-like particle (VLP) RSV vaccine candidate stimulat

152 ies of Env expressed in situ on pseudovirion virus-like particle (VLP) surfaces and soluble gp120 usi

153 erformed on infectious virus as well as in a virus-like particle (VLP) system indicate that the DI/DI

154 ted the effectiveness of baculovirus-derived virus-like particle (VLP) vaccination in generating Ab-m

155 tential applications in the development of a virus-like particle (VLP) vaccine as well as small-molec

156 with a multivalent GI.1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted w

157 We assessed 2 bivalent norovirus virus-like particle (VLP) vaccine candidate formulations

158 To overcome this, we used a virus-like particle (VLP) vaccine platform (PP7) for con

159 demiology findings and provides an update on virus-like particle (VLP) vaccine studies.

160 After vaccination with influenza A/PR8 virus-like particle (VLP) vaccine, in vivo and in vitro

161 hus may be more economically viable than the virus-like particle (VLP) vaccine.

162 adjuvanted bivalent intramuscular norovirus virus-like particle (VLP) vaccine.

163 Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current

164 L1 (the major papillomavirus virion protein) virus-like particle (VLP) vaccines are regarded as safe,

165 Vaccinating ferrets with virus-like particle (VLP) vaccines expressing COBRA HA p

166 ssed by the production and use of virus-free virus-like particle (VLP) vaccines that mimic the "empty

167 Among the potential anti-hRSV approaches are virus-like particle (VLP) vaccines, which, based on rese

168 RSV F virus-like particle (VLP) would be an efficient vaccine

169 We used a virus-like particle (VLP)-based approach to develop a va

170 Serological analysis of mice given virus-like particle (VLP)-based BKV vaccines confirmed t

171 Here, virus-like particle (VLP)-based entry assays demonstrate

172 tion, we tested the hypothesis that chimeric virus-like particle (VLP)-based vaccine platforms, which

173 nt of efficacious vaccines, human trials for virus-like particle (VLP)-based vaccines show promise in

174 comprises up to 90% and 22% of all reads in virus-like particle (VLP)-derived metagenomes and total

175 the CD40L is anchored on the membrane of SIV virus-like particle (VLP).

176 or products of plant-viral expression is the virus-like particle (VLP).

177 domain of matrix protein 2 (M2e) fused to a virus-like particle (VLP).

178 were examined in combination with influenza virus-like particles (VLP) (M8-VLP) expressing H5N1 infl

179 accines consist of major capsid protein (L1) virus-like particles (VLP) and are highly efficacious ag

180 Engineered virus-like particles (VLP) are attractive for fabricatin

181 d inflammatory gene networks using influenza virus-like particles (VLP) expressing HA and NA as immun

182 We used virus-like particles (VLP) to study the effect of acylat

183 med HPV-07, was selected to bind the Type 16 virus-like-particle (VLP) formed by the self-assembling

184 lles, dendrimers, liposomes, polyplexes, and virus-like-particles (VLP), as well as therapeutic relev

185 HIV-1 immature particle (virus-like particle [VLP]) assembly is mediated largely

186 Virus like particles (VLPs) of P22 containing ziconotide

187 g polymerizes on the plasma membrane to form virus like particles (VLPs) that have similar diameters

188 via display on multimerisation scaffolds or virus like particles (VLPs).

189 and a Gag-Pol-Nef polyprotein as Gag-induced virus-like particles (VLPs) (referred to as NYVAC-C and

190 acies of primary infection, P particles, and virus-like particles (VLPs) against NoV infection and di

191 ated for 50% blocking titer (BT50) values of virus-like particles (VLPs) against pig gastric mucin (P

192 p22/p18 cofractionates with Ty1 virus-like particles (VLPs) and affects VLP yield, prote

193 , we developed a panel of four GII.2 variant virus-like particles (VLPs) and compared their antigenic

194 sed to assess the binding specificity of CNV virus-like particles (VLPs) and identified alpha1,2-fuco

195 accine directs the synthesis and assembly of virus-like particles (VLPs) and induces immune responses

196 facilitate efficient release of VP40-driven virus-like particles (VLPs) and infectious virus.

197 the spontaneous interaction between HPV16 L1 virus-like particles (VLPs) and non-functionalized GNPs

198 which M2 ion channels are incorporated into virus-like particles (VLPs) and proton conductance is me

199 used for the production of prM/E-containing virus-like particles (VLPs) and secreted NS1 (sNS1) from

200 lution, two calibration standards were used: Virus-Like Particles (VLPs) and synthetic beads with a m

201 ns, mice were hyperimmunized with GII.4-2002 virus-like particles (VLPs) and the resulting MAbs were

202 1 vaccine which could combine the potency of virus-like particles (VLPs) and the simplicity of use of

203 graphy (cryo-ET) to directly visualize HIV-1 virus-like particles (VLPs) and virions tethered to huma

204 Assembly of HIV-1 Gag into virus-like particles (VLPs) appears to require an intera

205 NYVAC-Gag-Pol-Nef-infected cells Gag-induced virus-like particles (VLPs) are abundant.

206 Virus-like particles (VLPs) are an attractive alternativ

207 Virus-like particles (VLPs) are an attractive alternativ

208 Virus-like particles (VLPs) are an attractive vaccine ca

209 Virus-like particles (VLPs) are an attractive vaccine ca

210 Virus-like particles (VLPs) are attractive as a vaccine

211 Virus-like particles (VLPs) are non-infectious self-asse

212 Virus-like particles (VLPs) are stable protein cages der

213 uence and incorporated into Env-enriched HIV virus-like particles (VLPs) as a molecular adjuvant.

214 PxY-dependent budding of Marburg (MARV) VP40 virus-like particles (VLPs) as our model system, we iden

215 ession impair production and release of EBOV virus-like particles (VLPs) as well as infectivity of GP

216 f that trigger sequence-specific assembly of virus-like particles (VLPs) at much higher fidelity and

217 c differences over time, we created chimeric virus-like particles (VLPs) between the GII.4-1987 and G

218 Virus-like particles (VLPs) built on the Newcastle disea

219 xpression of VP40 leads to the production of virus-like particles (VLPs) by a mechanism that accurate

220 reacted with high titers against homologous virus-like particles (VLPs) by enzyme-linked immunoassay

221 owed that seven different genotypes of HuNoV virus-like particles (VLPs) can bind to canine gastroint

222 pe (Env) gp140 and Gag p55 (protein) or with virus-like particles (VLPs) containing SIVmac239 Env and

223 Immunization with virus-like particles (VLPs) containing the Newcastle dis

224 Recombinantly expressed virus-like particles (VLPs) could address these inherent

225 he successful assembly of nuclease-resistant virus-like particles (VLPs) depends delicately on the st

226 mmature lattice in noncrystalline, spherical virus-like particles (VLPs) derived from Gag.

227 (M), and protein immunogens, all expressing virus-like particles (VLPs) displaying membrane-anchored

228 Z-Tsg101 interaction and inhibits budding of virus-like particles (VLPs) driven by ectopic expression

229 ixture of engineered glycoproteins (GPs) and virus-like particles (VLPs) for three different filoviru

230 ctron microscopy (cryoEM) map of Chikungunya virus-like particles (VLPs) has been interpreted using t

231 Virus-like particles (VLPs) have become a promising plat

232 Virus-like particles (VLPs) have been extensively explor

233 Viral proteins and Virus-Like Particles (VLPs) have been of particular inte

234 Virus-like particles (VLPs) have emerged as important an

235 al transition by following hemifusion of WNV virus-like particles (VLPs) in a single particle format.

236 retrotransposons Ty1 and Ty3, which assemble virus-like particles (VLPs) in intracytoplasmic ribonucl

237 also contributes to efficient production of virus-like particles (VLPs) in transfected cells.

238 oat protein of murine polyomavirus and forms virus-like particles (VLPs) in vitro.

239 Spiked virus-like particles (VLPs) in wasp venom have clearly b

240 MDMs treated with inactivated EBOV and Ebola virus-like particles (VLPs) induced NF-kappaB activation

241 ng epitopes in human papillomavirus (HPV) L1 virus-like particles (VLPs) is the structural basis of p

242 lergen, displayed in a repetitive fashion on virus-like particles (VLPs) may fulfill these criteria.

243 t cells and were shown to self-assemble into virus-like particles (VLPs) morphologically similar to t

244 HIV-1, we performed comparative analyses of virus-like particles (VLPs) obtained by expression of wi

245 licensed prophylactic HPV vaccines based on virus-like particles (VLPs) of the L1 major capsid prote

246 he three currently licensed vaccines contain virus-like particles (VLPs) of the L1 major capsid prote

247 Here we show the structure of MrNV virus-like particles (VLPs) produced by recombinant expr

248 ge attack with a pool of live or heat-killed virus-like particles (VLPs) purified from the fecal micr

249 eries metagenomic study of DNA isolated from virus-like particles (VLPs) recovered from fecal samples

250 Antigenicity of virus-like particles (VLPs) representative of clusters I

251 d individual, we synthetically reconstructed virus-like particles (VLPs) representing early and late

252 re we show that intranasal administration of virus-like particles (VLPs) results in splenic B-cell re

253 uman papillomavirus (HPV) vaccines, based on virus-like particles (VLPs) self-assembled from major ca

254 Using Human Papillomavirus virus-like particles (VLPs) spiked in 10% fetal bovine s

255 f VP40 leads to the production and egress of virus-like particles (VLPs) that accurately mimic the bu

256 uced by rNDVs was able to self-assemble into virus-like particles (VLPs) that are morphologically sim

257 of host cells results in its packaging into virus-like particles (VLPs) that are subsequently releas

258 coexpression led to coordinated assembly of virus-like particles (VLPs) that were morphologically an

259 Here we used phage display against virus-like particles (VLPs) to isolate seven human monoc

260 t Gag proteins are soluble but assemble into virus-like particles (VLPs) upon addition of nucleic aci

261 -1999, GII-12-1998, GI-1-2001, and GI-3-2002 virus-like particles (VLPs) were determined by enzyme-li

262 ells results in the formation and budding of virus-like particles (VLPs) which mimic the budding proc

263 Virus-like particles (VLPs) with increased density of En

264 irus (CCMV), we demonstrate the synthesis of virus-like particles (VLPs) with one end of the packaged

265 Virus-like particles (VLPs), comprised of viral structur

266 r of IBV E is required for the production of virus-like particles (VLPs), implicating this form of th

267 CpGs into nanoparticles, in particular into virus-like particles (VLPs), improves the pharmacologica

268 , the PFV Gag-Pol proteins can assemble into virus-like particles (VLPs), in contrast to the orthoret

269 capsomers, obtained from the disassembly of virus-like particles (VLPs), were incubated with nuclear

270 ave previously established a system based on virus-like particles (VLPs), which allows tracking of VL

271 a novel tetravalent dengue vaccine by using virus-like particles (VLPs), which are noninfectious bec

272 domain efficiently produce genome-free VEEV virus-like particles (VLPs), which are very similar in s

273 lone is usually sufficient for production of virus-like particles (VLPs).

274 mulation of L1-dsRNA/SsMBV1 and stability of virus-like particles (VLPs).

275 tion to an extended rod-like conformation in virus-like particles (VLPs).

276 teins can assemble in vitro to form immature virus-like particles (VLPs).

277 a novel RNAi scaffold, packaged within Qbeta virus-like particles (VLPs).

278 d loss of function, preventing release of NA virus-like particles (VLPs).

279 roduction of recombinant proteins, including virus-like particles (VLPs).

280 These genome-free virions are referred to as virus-like particles (VLPs).

281 ies (MAbs) against GII.4.2006 and GII.4.2009 virus-like particles (VLPs).

282 psid, and recombinant CP spontaneously forms virus-like particles (VLPs).

283 ein (G) autonomously induce the formation of virus-like particles (VLPs).

284 ovel tetravalent dengue vaccine by utilizing virus-like particles (VLPs).

285 -meric E2p that displays 20 spikes mimicking virus-like particles (VLPs).

286 valent prophylactic HPV vaccines composed of virus-like particles (VLPs).

287 on with virus or immunization with influenza virus-like particles (VLPs).

288 CDots) antiviral activity to human norovirus virus-like-particles (VLPs), GI.1 and GII.4 VLPs.

289 However, virus-like particles +Vpx treatment of activated CD4(+)

290 l Toll-like receptor 9 agonist packaged into virus-like particles, was designed to stimulate the immu

291 from CCR5 at high density on the surface of virus-like particles, we can efficiently induce high-tit

292 With this knowledge, and using virus-like particles, we could demonstrate that the last

293 Using cryo-electron tomography of Ebola virus-like particles, we determined a three-dimensional

294 Virus-like particles were stained to confirm the presenc

295 as that of genogroup I.1 and genogroup II.4 virus-like particles, were compared in a series of 109 d

296 versatile woodchuck hepadnavirus core-based virus-like particle (WHcAg-VLP) to generate hybrid VLPs

297 QbG10 (bacteriophage Qbeta-derived virus-like particle with CpG-motif G10 inside), a novel

298 y digesting immature particles and assembled virus-like particles with recombinant HIV-1 protease and

299 developed a plasmid-based system to produce virus-like particles with the ability to infect cells an

300 isoleucine abrogated VP2 incorporation into virus-like particles without affecting the ability for V